China SXT Pharmaceuticals Inc(SXTC) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -645.01 | Insider Own | 15% | Shs Outstand | 10.4M | Perf Week | -49.59% |
| Market Cap | 0.00B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 8.8M | Perf Month | -98.69% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | - | Inst Own | 0.01% | Short Float | 0.08% | Perf Quarter | -99.37% |
| Income | -0.01B | P/S | 2.22 | EPS this Y | - | Inst Trans | 12.07% | Short Ratio | 0.03 | Perf Half Y | -99.98% |
| Sales | 0.00B | P/B | 0 | EPS next 5Y | - | ROA | -22% | Short Interest | 0.01M | Perf YTD | -100% |
| Book/sh | 2480.58 | P/C | 0.09 | EPS past 3/5Y | 93.01% 84.85% | ROE | -27.49% | 52W High | -100% ($8375880.00) | Perf Year | -100% |
| Cash/sh | 41 | P/FCF | - | Sales past 3/5Y | -16.74% -24.94% | ROIC | -20.41% | 52W Low | 12.2% ($3.28) | Perf 3Y | -100% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 97.52% | Gross Margin | 21.85% | Volatility(W/M) | 18.74% 53.97% | Perf 5Y | -100% |
| Dividend TTM | - | EV/Sales | -21.52 | Sales Y/Y TTM | -34.63% | Oper. Margin | -630.63% | ATR (14) | 68 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 7.25 | EPS Q/Q | - | Profit Margin | -545.24% | RSI (14) | 27.81 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 7.93 | Sales Q/Q | - | SMA20 | -94.27% ($64.22) | Beta | 1.89 | Target Price | - |
| Payout | - | Debt/Eq | 0.04 | Earnings | - | SMA50 | -98.08% ($191.67) | Rel Volume | 0.82 | Prev Close | $3.55 |
| Employees | 56 | LT Debt/Eq | 0.02 | EPS/Sales Surpr. | - | SMA200 | -99.98% ($18400) | Avg Volume(3M) | 0.22M | Price | $3.68 |
| IPO | 2019/1/4 | Option/Short | No/Yes | Trades | 7968 | Volume | 178,422 | Change | 3.66% |
💊 China SXT Pharmaceuticals (SXTC) is a China-based pharmaceutical company and a micro-cap healthcare stock that deals with traditional Chinese medicine ingredients. Although it is small in scale, it continues to operate in the specialty and generic drug fields against the backdrop of the Chinese pharmaceutical market.
Over the past 1 year, on the lower side
100% below its 1-year high.
Traded about as much as usual. That is 82% of its average volume.
SXTC has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $222. Peers typically go for $212.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.0%.
Tap to view numbers
It ranks #80 of 83 in the industry
Based on market cap of $3M.
RDHL#78 Redhill Biopharma Ltd ADR $4M PER - 
AKAN#79 Akanda Corp $3M PER - SXTC#80 China SXT Pharmaceuticals Inc $3M PER - 
PRFX#81 PRF Technologies Ltd $2M PER - 
SBFM#82 Sunshine Biopharma Inc $2M PER - 
FAQ
What kind of company is SXTC?
SXTC belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of SXTC?
The market cap of SXTC is approximately $3M, ranking 5,768 within its sector.
What is the 52-week high and low for SXTC?
SXTC has recorded a 52-week high of $8375880.00 and a low of $3.28.
